Literature DB >> 7796508

Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries. The role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation.

R L Geary1, N Koyama, T W Wang, S Vergel, A W Clowes.   

Abstract

BACKGROUND: Heparin is a potent inhibitor of smooth muscle cell (SMC) growth and intimal hyperplasia in animal models but has been ineffective in inhibiting restenosis in humans. This difference may relate to flaws in clinical study design or, alternatively, to interspecies differences in SMC response to heparin. To determine whether heparin could inhibit intimal hyperplasia in a species more closely related to humans, we studied the effect of a low-molecular-weight heparin (LMWH) on baboon SMC proliferation and migration in culture and in arteries subjected to experimental angioplasty. METHODS AND
RESULTS: LMWH or saline was infused continuously after experimental angioplasty of baboon peripheral arteries (six animals per group). After 28 days, bromodeoxyuridine (BrdU) was given to label proliferating cells, and balloon-injured arteries were perfusion-fixed in situ and removed for analysis. All arteries had reendothelialized (Evans blue dye exclusion). LMWH increased partial thromboplastin time (LMWH, 81.7 +/- 8.4 seconds versus saline, 34.7 +/- 0.8 seconds [mean +/- SEM]; P = .004) but failed to inhibit intimal thickening or SMC proliferation (intimal area: LMWH, 0.19 +/- 0.03 mm2 versus saline, 0.21 +/- 0.03 mm2; BrdU labeling: LMWH, 2.9 +/- 0.6% versus saline, 2.4 +/- 0.4%; P = NS). In culture, LMWH and standard heparin (100 micrograms/mL) significantly inhibited serum-induced but not platelet-derived growth factor (PDGF-BB)-induced SMC proliferation (% control, serum: LMWH, 60.5 +/- 4.0%, P = .0002; standard heparin, 29.4 +/- 8.2%, P = .0001; % control, PDGF-BB: LMWH, 117.7 +/- 11.3%, P = NS; standard heparin, 90.9 +/- 14.4%, P = NS) and SMC migration (% control, serum: LMWH, 15.3 +/- 1.9%, P = .0198; standard heparin, 26.4 +/- 13.8%, P = .0032; % control, PDGF-BB: LMWH, 98.5 +/- 14.3%, P = NS; standard heparin, 100.0 +/- 13.5%, P = NS).
CONCLUSIONS: LMWH failed to inhibit intimal hyperplasia in a baboon angioplasty model. Furthermore, LMWH blocked serum-induced but not PDGF-BB-induced SMC proliferation and migration in culture. Thus, heparin-sensitive and -insensitive pathways exist for SMC activation. The relative importance of each pathway induced by injury may vary between species and thus account for different responses to heparin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796508     DOI: 10.1161/01.cir.91.12.2972

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro.

Authors:  N Koyama; J Seki; S Vergel; E J Mattsson; T Yednock; N L Kovach; J M Harlan; A W Clowes
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors.

Authors:  J Pelisek; S Armeanu; S Nikol
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

3.  Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers.

Authors:  Patrick C H Hsieh; Michael E Davis; Joseph Gannon; Catherine MacGillivray; Richard T Lee
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

4.  Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia.

Authors:  Nozomi Fukai; Richard D Kenagy; Lihua Chen; Lu Gao; Guenter Daum; Alexander W Clowes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-10       Impact factor: 8.311

5.  Electrochemically modulated nitric oxide (NO) releasing biomedical devices via copper(II)-Tri(2-pyridylmethyl)amine mediated reduction of nitrite.

Authors:  Hang Ren; Jianfeng Wu; Chuanwu Xi; Nicolai Lehnert; Terry Major; Robert H Bartlett; Mark E Meyerhoff
Journal:  ACS Appl Mater Interfaces       Date:  2014-03-14       Impact factor: 9.229

6.  Predicting in vivo efficacy of potential restenosis therapies by cell culture studies: species-dependent susceptibility of vascular smooth muscle cells.

Authors:  Hila Epstein; Laura Rabinovich; Shmuel Banai; Vicktoria Elazar; Jianchuan Gao; Michael Chorny; Haim D Danenebrg; Gershon Golomb
Journal:  Open Cardiovasc Med J       Date:  2008-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.